Jasper van der Lugt

Dual targeting of <i>CD155</i>/<i>TIGIT</i> and <i>PD-L1</i>/<i>PD-1</i> immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma

Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies

Growth recovery in patients with <i>BRAF</i> altered pediatric low-grade gliomas (LGG) after discontinuation of tovorafenib.

CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

CTNI-09. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL

LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL

Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations

Ultra-fast deep-learned CNS tumour classification during surgery

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600–Mutant Pediatric High-Grade Glioma

Assessment of Cancer Predisposition Syndromes in a National Cohort of Children With a Neoplasm

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.

LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

CTNI-37. CLINICAL ACTIVITY OF RAF INHIBITOR TOVORAFENIB ACCORDING TO PRIOR MAPK INHIBITOR TREATMENT IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600–mutant pediatric low-grade glioma (pLGG).

CTNI-68. FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with <i>RAF</i>-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 NivEnt.

RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i>

ETMR-06. Molecular and clinical characteristics of CNS tumors with<i>BCOR(L1</i>) fusion/internal tandem duplication

P02.07 Characterization of the tumor immune microenvironment of pediatric posterior fossa A ependymomas

Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV